ACCD provides non-dilutive, asset-based financing for pivotal stage clinical development programs for biopharmaceutical companies.
We take 100% of the financial risk. Success payments are due only if the drug is approved and these may include a royalty component. Deals can be structured to allow favourable P&L accounting treatment both under US-GAAP and IFRS. The cost for such funding is targeted to be competitive with internal risk-adjusted costs.
Should it be required, our co-development portfolio company Launch Therapeutics is able to provide clinical and regulatory operational expertise to facilitate clinical trial execution globally, increasing the efficiency and quality of the trials.
ACCD financing enables companies to:
Assets will typically be Phase 3 ready or pivotal, with a high probability of reaching approval and successful commercialisation within a few years. The assets can be new molecular entities (NMEs) or already approved products being trialled in new indications. Single or multiple assets can be considered for global or regional development programs.
Investment size is flexible between $50m - $500m. We offer customised financing solutions across the capital structure, and work with companies to evaluate a combination of equity and CCD financing where appropriate. Diligence is rapid, leading to an initial go/no-go decision in weeks.
If you'd like additional information about Abingworth's pioneering Clinical Co‑Development solution, please contact Bali Muralidhar
Contact BaliWith over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.
Find out moreWe also understand the different challenges faced by later-stage companies, both public and private, as their programs move through the clinic to market. Our Development Stage strategy is focused on these later-stage companies.
Find out moreWe use cookies on this site to enhance your user experience.
By clicking the Accept button, you agree to us doing so. Find out more here.